Axeq shares the technical resources of Macrogen in South Korea, which has been named one of the world’s top-five next-generation sequencing centers and the second largest commercial NGS service provider worldwide. In the third quarter of 2012, Macrogen installed Life Technologies’ Ion Proton and Illumina’s HiSeq2500 in preparation for fast turnaround clinical sequencing service after its addition of a dozen Illumina HiSeq2000 platforms a few months earlier. Our bioinformatics team is composed of tens of full-time experts who have extensive NGS data experience and provide necessary aids: from designing the project to mining the data for publication.
Exome sequencing with various options has been the most popular application for the last two years, and RNA sequencing recently became one of the major NGS applications. At Axeq, we pride ourselves in extremely reliable exome data from DNA derived from various sources including FFPE tissues; and high-quality RNA sequencing data even from a few nanograms of total RNA as starting material as well as “proven” RNA-Seq analysis pipelines and statistic data analysis that has yielded the publication on lung cancer causing fusion gene discovery. Axeq offers start-to-end customized targeted sequencing services from panel probe design to data analysis for finding clinically relevant answers. The recently announced industry-leading promotional price of Axeq is expected to attract those who speculate the markets and hold their investment.
Axeq shares the expertise of Macrogen in high depth human whole-genome resequencing and analysis capabilities including SNV, CNV, and other structural variations. As a participant in the Illumina Genome Network (IGN) for over four years, it has been proven that we are an acknowledged and leading provider of high-quality whole-genome sequencing with fast turnaround.
Since 2011, as a valuable addition to the exome sequencing service with variant calling and annotation, Axeq has been offering Exome Turnkey Discovery service to determine disease-causing variant candidates from a proband and its familial member sequencing data.
Today’s marketing statement of Axeq, “pick the low hanging fruit with best-of-class data and industry leading price”, well depicts its confidence in offering target focused, cost- and time- efficient genomic research services.